INVO Fertility

INVO Fertility is a fertility-services company commercializing the INVOcell intravaginal culture (IVC) system, an FDA-cleared medical device that enables fertilization and early embryo development to occur inside a woman's body rather than in a traditional IVF lab incubator. The company operates a clinic network and partners with reproductive endocrinology practices to expand access to lower-cost assisted reproductive technology. INVO Fertility has received Nasdaq notifications for late filings of its 2025 Form 10-K and Q1 2026 Form 10-Q and has executed two reverse stock splits in the prior 12 months (1-for-3 in July 2025 and 1-for-5 in March 2026) to maintain listing compliance.